Jadenu Warnings

Therapy with JADENU should be initiated and maintained by physicians experience in the treatment of chronic iron overload due to blood transfusions.
Deferasirox is contraindicated in patients with moderate and severe renal impairment (see Contraindications) and has not been studied in patients with severe hepatic impairment.
The following are clinically significant adverse events (see Precautions): Acute renal failure; Hepatic failure; Gastrointestinal haemorrhage and perforations.
JADENU film-coated tablets is a strength-adjusted formulation of deferasirox with higher bioavailability compared to deferasirox dispersible tablets (see Pharmacology: Pharmacokinetics under Actions).
JADENU requires a different dosing regimen and method of administration compared to deferasirox dispersible tablets. To avoid dosing errors, it is important that prescriptions of deferasirox specify both the type of formulation (dispersible tablet or film-coated tablet) and the prescribed dose in mg/kg/day.
This medicine is also available as a tablet that is meant to be dissolved in liquid before drinking. The doses of these two formulations are not the same. Be sure that the patient is taking the right type of deferasirox. Patients must be advised to check with the doctor, nurse or pharmacist if not sure.